Asia Future Biomedical

Asia Future Biomedical (AFB) is a Taiwan-based biotechnology company specializing in the development of ultra-sensitive protein detection technologies and advanced diagnostic solutions. The company is best known for its Immunomagnetic Reduction (IMR) platform, which enables the precise measurement of low-concentration biomarkers in blood, particularly for the early detection of Alzheimer's disease and other neurodegenerative disorders. Beyond diagnostics, AFB is involved in the development of cell therapies and precision medicine tools aimed at improving patient outcomes in oncology and neurology. The company provides both diagnostic kits and laboratory testing services to clinical and research institutions globally.